FDA Peptide Advisory Panel Faces Questions About Members’ Potential Conflicts of Interest

Vials and syringes used for injectable medications are shown as the FDA’s Pharmacy Compounding Advisory Committee meets to consider whether several synthetic peptides should become eligible for pharmacy compounding despite safety concerns raised by FDA scientists. Tada Images/Shutterstock

Tomorrow and Friday, the Food and Drug Administration’s (FDA) Pharmacy Compounding Advisory Committee (PCAC) will vote on whether to recommend approval of seven peptides previously banned due to health risks. The proposal faces opposition from FDA scientists.

With Health and Human Services Secretary Robert F. Kennedy, Jr., who says he has used peptides, openly advocating for approval, and a PCAC board stacked with members who operate clinics, pharmacies, or online businesses that promote peptides, there is little doubt about the outcome.